News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 09 - 10

Efung News | Real Biotechnology's Non-Camptothecin Toxin Debuts at CBI 2026, Breaking Through the ADC Drug Resistance Bottleneck

Recently, the CBI 2026 Biomedical Innovation Expo concluded in Suzhou, with an exhibition area of over 36,000 square meters and more than 20,000 participants gathered on site to jointly create a new industry ecosystem. The conference featured multiple parallel forums. At the ADC New Drug Discovery and Front-End Technology Innovation Forum, Dr. Dang Qun, President of Real Biotechnology, shared the company's latest achievements in overcoming ADC drug resistance with its novel non-camptothecin TOPO1 inhibitor platform.ImagePrecision therapeutic approaches represented by next-generation ADC dr...

浏览次数：0

查看详情>>

发布时间: 2026 - 09 - 09

Efung Knowledge Planet | 2026 National Medical Insurance Negotiations in Progress: Collectively Competing for the Medical Insurance "Admission Ticket"

The 2026 National Medical Insurance Drug Catalog Adjustmentachieves full-process parallelism with the Commercial Insurance Innovative Drug Catalog for the first time,opening up a more strategically flexible"walking on two legs" pathway.This article is approximately 2,989 words, with a reading time of about 3 minutes.On the morning of September 8, the three-and-a-half-day on-site negotiation for the National Basic Medical Insurance Catalog officially concluded. On September 9, price negotiation for the Commercial Health Insurance Innovative Drug Catalog officially launched, with final...

浏览次数：0

查看详情>>

发布时间: 2026 - 09 - 04

Efung Hornor | Efung Capital Named to FOFWEEKLY's 2026 Investment Institution Soft Power Ranking – H

Today, FOFWEEKLY officially released its 2026 Investment Institution Soft Power Ranking, and Efung Capital was honored with the Healthcare TOP30 award.In 2026, the equity investment industry finds itself at a critical intersection of "divergence" and "reconstruction." The market has moved past the initial phase of structural recovery and has formally entered a new cycle where legacy holdings coexist with the pursuit of new growth opportunities. Driven by sustained policy guidance and the commercial deployment of hard technologies, the global competitiveness o...

浏览次数：1

查看详情>>

发布时间: 2026 - 09 - 03

Efung News | Trinomab’s Global First Anti-RSV Monoclonal Antibody Xinduotuo®, Offering One-Shot, 9-M

On September 3, 2026, Zhuhai Trinomab Pharmaceutical Co., Ltd. (Stock Code: 688806, hereinafter referred to as "Trinomab") reached another significant milestone!Following the approval of Xintituo® (Generic Name: Stedostat Monoclonal Antibody Injection), the world's first innovative next-generation "tetanus shot," the company's independently developed global first recombinant anti-respiratory syncytial virus (RSV) fully human monoclonal antibody — Xinduotuo® (Generic Name: Ritevimab Monoclonal Antibody Injection, formerly known as TNM001 Injection) — has of...

浏览次数：4

查看详情>>